Resveratrol prevents AngII-induced hypertension via AMPK activation and RhoA/ROCK suppression in mice

Hypertension Research

Volumn 37, Issue 9, 2014, Pages 803-810

  Cao, Xia ^a   Luo, Tao ^a   Luo, Xi ^a   Tang, Zhiyi ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN II; ANTIHYPERTENSIVE AGENT; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE DIPHOSPHATE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MYOSIN; MYOSIN HEAVY CHAIN; MYOSIN LIGHT CHAIN; MYOSIN PHOSPHATASE TARGETING SUBUNIT 1; RESVERATROL; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; THIAZOVIVIN; UNCLASSIFIED DRUG; ADENYLATE KINASE; RHO KINASE; STILBENE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; AORTA CONSTRICTION; ARTERY CONSTRICTION; ARTICLE; BLOOD PRESSURE REGULATION; BODY WEIGHT; CELL CULTURE; CHRONIC DRUG ADMINISTRATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; ENZYME REPRESSION; EX VIVO STUDY; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; HYPERTENSION; MALE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; RNA INTERFERENCE; SMOOTH MUSCLE CONTRACTION; SYSTOLIC BLOOD PRESSURE; VASCULAR SMOOTH MUSCLE; ANIMAL; BLOOD PRESSURE; CHEMICALLY INDUCED; DRUG EFFECTS; METABOLISM; MUSCLE CONTRACTION; PHOSPHORYLATION; SMOOTH MUSCLE FIBER;

ADENYLATE KINASE; ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; HYPERTENSION; MICE; MUSCLE CONTRACTION; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHOSPHORYLATION; RHO-ASSOCIATED KINASES; RHOA GTP-BINDING PROTEIN; STILBENES;

EID: 84906485679     PISSN: 09169636     EISSN: 13484214     Source Type: Journal    
DOI: 10.1038/hr.2014.90     Document Type: Article

References (39)

1. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ, Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension 2003; 42: 1206-1252.
2. Lawes CM, Vander Hoorn S, Rodgers A, International Society of Hypertension. Global burden of blood-pressure-related disease, 2001. Lancet 2008; 371: 1513-1518.
3. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension 2008; 51: 1403-1419.
4. Kannel WB. Fifty years of framingham study contributions to understanding hypertension. J Hum Hypertens 2000; 14: 83-90.
5. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275: 218-220.
6. Franco JG, Lisboa PC, Lima NS, Amaral TA, Peixoto-Silva N, Resende AC, Oliveira E, Passos MC, Moura EG. Resveratrol attenuates oxidative stress and prevents steatosis and hypertension in obese rats programmed by early weaning. J Nutr Biochem 2013; 24: 960-966.
7. Barger JL, Kayo T, Pugh TD, Prolla TA, Weindruch R. Short-term consumption of a resveratrol-containing nutraceutical mixture mimics gene expression of long-term caloric restriction in mouse heart. Exp Gerontol 2008; 43: 859-866.
8. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, Wang Y, Raederstorff D, Morrow JD, Leeuwenburgh C, Allison DB, Saupe KW, Cartee GD, Weindruch R, Prolla TA. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS ONE 2008; 3: e2264.
9. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5: 493-506.
10. Baur JA, Pearson KJ, Price NL, Jamieson HA, Lerin C, Kalra A, Prabhu VV, Allard JS, Lopez-Lluch G, Lewis K, Pistell PJ, Poosala S, Becker KG, Boss O, Gwinn D, Wang M, Ramaswamy S, Fishbein KW, Spencer RG, Lakatta EG, Le Couteur D, Shaw RJ, Navas P, Puigserver P, Ingram DK, de Cabo R, Sinclair DA. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006; 444: 337-342.
11. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, Messadeq N, Milne J, Lambert P, Elliott P, Geny B, Laakso M, Puigserver P, Auwerx J. Resveratrol improves mitochondrial function and protects against metabolic disease by activating sirt1 and pgc-1alpha. Cell 2006; 127: 1109-1122.
12. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, Swindell WR, Kamara D, Minor RK, Perez E, Jamieson HA, Zhang Y, Dunn SR, Sharma K, Pleshko N, Woollett LA, Csiszar A, Ikeno Y, Le Couteur D, Elliott PJ, Becker KG, Navas P, Ingram DK, Wolf NS, Ungvari Z, Sinclair DA, de Cabo R. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8: 157-168.
13. Ramadori G, Gautron L, Fujikawa T, Vianna CR, Elmquist JK, Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009; 150: 5326-5333.
14. Kanamori H, Takemura G, Goto K, Tsujimoto A, Ogino A, Takeyama T, Kawaguchi T, Watanabe T, Morishita K, Kawasaki M, Mikami A, Fujiwara T, Fujiwara H, Seishima M, Minatoguchi S. Resveratrol reverses remodeling in hearts with large, old myocardial infarctions through enhanced autophagy-Activating amp kinase pathway. Am J Pathol 2013; 182: 701-713.
15. Brasnyo P, Molnar GA, Mohas M, Marko L, Laczy B, Cseh J, Mikolas E, Szijarto IA, Merei A, Halmai R, Meszaros LG, Sumegi B, Wittmann I. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the akt pathway in type 2 diabetic patients. Br J Nutr 2011; 106: 383-389.
16. Crandall JP, Oram V, Trandafirescu G, Reid M, Kishore P, Hawkins M, Cohen HW, Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J Gerontol A Biol Sci Med Sci 2012; 67: 1307-1312.
17. Lee-Young RS, Griffee SR, Lynes SE, Bracy DP, Ayala JE, McGuinness OP, Wasserman DH. Skeletal muscle amp-Activated protein kinase is essential for the metabolic response to exercise in vivo. J Biol Chem 2009; 284: 23925-23934.
18. Kemp BE, Stapleton D, Campbell DJ, Chen ZP, Murthy S, Walter M, Gupta A, Adams JJ, Katsis F, van Denderen B, Jennings IG, Iseli T, Michell BJ, Witters LA. Amp-Activated protein kinase, super metabolic regulator. Biochem Soc Trans 2003; 31: 162-168.
19. Winder WW, Hardie DG. Amp-Activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. Am J Physiol 1999; 277: E1-10.
20. Dong Y, Zhang M, Wang S, Liang B, Zhao Z, Liu C, Wu M, Choi HC, Lyons TJ, Zou MH. Activation of amp-Activated protein kinase inhibits oxidized ldl-triggered endoplasmic reticulum stress in vivo. Diabetes 2010; 59: 1386-1396.
21. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH. Ampkalpha2 deletion causes aberrant expression and activation of nad(p)h oxidase and consequent endothelial dysfunction in vivo: role of 26s proteasomes. Circ Res 2010; 106: 1117-1128.
22. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC, Zou MH. Reduction of ampactivated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 2010; 121: 792-803.
23. Wang S, Xu J, Song P, Viollet B, Zou MH. In vivo activation of amp-Activated protein kinase attenuates diabetes-enhanced degradation of gtp cyclohydrolase i. Diabetes 2009; 58: 1893-1901.
24. Buhl ES, Jessen N, Pold R, Ledet T, Flyvbjerg A, Pedersen SB, Pedersen O, Schmitz O, Lund S. Long-term aicar administration reduces metabolic disturbances and lowers blood pressure in rats displaying features of the insulin resistance syndrome. Diabetes 2002; 51: 2199-2206.
25. Rivera L, Moron R, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese zucker rats. Biochem Pharmacol 2009; 77: 1053-1063.
26. Dolinsky VW, Chakrabarti S, Pereira TJ, Oka T, Levasseur J, Beker D, Zordoky BN, Morton JS, Nagendran J, Lopaschuk GD, Davidge ST, Dyck JR. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim Biophys Acta 2013; 1832: 1723-1733.
27. Dolinsky VW, Jones KE, Sidhu RS, Haykowsky M, Czubryt MP, Gordon T, Dyck JR. Improvements in skeletal muscle strength and cardiac function induced by resveratrol during exercise training contribute to enhanced exercise performance in rats. J Physiol 2012; 590: 2783-2799.
28. Dolinsky VW, Rueda-Clausen CF, Morton JS, Davidge ST, Dyck JR. Continued postnatal administration of resveratrol prevents diet-induced metabolic syndrome in rat offspring born growth restricted. Diabetes 2011; 60: 2274-2284.
29. Wang S, Song P, Zou MH. Inhibition of amp-Activated protein kinase alpha (ampkalpha) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and sirt1. J Biol Chem 2012; 287: 8001-8012.
30. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY. Statins activate amp-Activated protein kinase in vitro and in vivo. Circulation 2006; 114: 2655-2662.
31. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin ii: modulated by g proteins, kinases, and myosin phosphatase. Physiol Rev 2003; 83: 1325-1358.
32. Sward K, Dreja K, Susnjar M, Hellstrand P, Hartshorne DJ, Walsh MP. Inhibition of rho-Associated kinase blocks agonist-induced ca2+ sensitization of myosin phosphorylation and force in guinea-pig ileum. J Physiol 2000; 522(Pt 1), 33-49.
33. Wettschureck N, Offermanns S. Rho/rho-kinase mediated signaling in physiology and pathophysiology. J Mol Med (Berl) 2002; 80: 629-638.
34. Loirand G, Guerin P, Pacaud P. Rho kinases in cardiovascular physiology and pathophysiology. Circ Res 2006; 98: 322-334.
35. Bishop AL, Hall A. Rho gtpases and their effector proteins. Biochem J 2000; 348(Pt 2), 241-255.
36. Shirwany NA, Zou MH. Ampk in cardiovascular health and disease. Acta Pharmacol Sin 2010; 31: 1075-1084.
37. Noma K, Rikitake Y, Oyama N, Yan G, Alcaide P, Liu PY, Wang H, Ahl D, Sawada N, Okamoto R, Hiroi Y, Shimizu K, Luscinskas FW, Sun J, Liao JK. Rock1 mediates leukocyte recruitment and neointima formation following vascular injury. J Clin Invest 2008; 118: 1632-1644.
38. Kroll J, Epting D, Kern K, Dietz CT, Feng Y, Hammes HP, Wieland T, Augustin HG. Inhibition of rho-dependent kinases rock i/ii activates vegf-driven retinal neovascularization and sprouting angiogenesis. Am J Physiol Heart Circ Physiol 2009; 296: H893-H899.
39. Kanazawa I, Yamaguchi T, Yano S, Yamauchi M, Sugimoto T. Activation of amp kinase and inhibition of rho kinase induce the mineralization of osteoblastic mc3t3-e1 cells through endothelial nos and bmp-2 expression. Am J Physiol Endocrinol Metab 2009; 296: E139-E146.